IBRX vs CRIS vs NKTR vs FATE

For growth investors, ImmunityBio, Inc.

(IBRX) is the stronger pick with 22. 7% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Analysts rate ImmunityBio, Inc. (IBRX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ImmunityBio, Inc.

(IBRX) delivered a total return of -53. 6%, compared to -99. 7% for Curis, Inc. (CRIS). Over 10 years, the gap is even starker: FATE returned +40. 5% versus CRIS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Nektar Therapeutics (NKTR) is the lower-risk stock at 1.

85β versus ImmunityBio, Inc. 's 2. 21β — meaning IBRX is approximately 20% more volatile than NKTR relative to the S&P 500. On balance sheet safety, Curis, Inc. (CRIS) carries a lower debt/equity ratio of 30% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ImmunityBio, Inc.

(IBRX) is pulling ahead at 22. 7% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Curis, Inc. grew EPS 91. 6% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, IBRX leads at 150. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Curis, Inc.

(CRIS) is the more profitable company, earning -80. 3% net margin versus -28. 0% for ImmunityBio, Inc. — meaning it keeps -80. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NKTR leads at -236. 8% versus -23. 3% for IBRX. At the gross margin level — before operating expenses — IBRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Nektar Therapeutics (NKTR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

ImmunityBio, Inc. (IBRX) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NKTR: -59. 1%, IBRX: -7. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IBRX is a small-cap high-growth stock; CRIS is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.